Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients

By Carlini Paolo   Michelotti Andrea   Ferretti Gianluigi   Ricci Sergio   Giannarelli Diana   Pellegrini Manuela   Cresti Nicola   Cosimo Serena Di   Bria Emilio   Papaldo Paola   Fabi Alessandra   Ruggeri Enzo Maria   Milella Michele   Alimonti Andrea   Salesi Nello   Cognetti Francesco  

Cancer Investigation, Vol. 25, Iss. 2, 2007-03 ,pp. : 102-105

Informa Healthcare

Access to resources Recommend Favorite

Estrogen and estrogen–progestin replacement therapy and risk of postmenopausal breast cancer in Canada

By Kirsh V.  

Cancer Causes and Control, Vol. 13, Iss. 6, 2002-08 ,pp. : 583-590

Springer Publishing Company

Access to resources Recommend Favorite

Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States)

By Newcomer L.M.  

Cancer Causes and Control, Vol. 14, Iss. 3, 2003-04 ,pp. : 225-233

Springer Publishing Company

Access to resources Recommend Favorite

Quality of Life in Postmenopausal Patients with Breast Cancer after Failure of Tamoxifen: Formestane Versus Megestrol Acetate as Second-line Hormonal Treatment

By Bernhard J.   Castiglione-Gertsch M.   Schmitz S.-F.H.   Thurlimann B.   Cavalli F.   Morant R.   Fey M.F.   Bonnefoi H.   Goldhirsch A.   Hurny C.  

European Journal of Cancer, Vol. 35, Iss. 6, 1999-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Aminoglutethimide: a Phase II Multicentre Multinational Study

By Exemestane Study Group   Thurlimann B.   Paridaens R.   Serin D.   Bonneterre J.   Roche H.   Murray R.   di Salle E.   Lanzalone S.   Zurlo M.G.   Piscitelli G.  

European Journal of Cancer, Vol. 33, Iss. 11, 1997-10 ,pp. : 1767-1773

Elsevier

Access to resources Recommend Favorite